Showing results (411-420 of 484) with videos related to

Sort By:
Pageof 49
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Clinical Lung Cancer|September 23, 2023
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart ReviewJürgen Wolf, Pierre-Jean Souquet, Koichi Goto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Frontiers in Oncology|April 10, 2023
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI stagingSaud Alhusaini, Tyler A Lanman, Ryan B Ko, et al.
Research Square|June 29, 2026
Challenges in AI Based Tumor Board Case Summarization and RecommendationsWen-Wai Yim, Hendrik Damm, Tabea M G Pakull, et al.
Diabetes|June 19, 2015
Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 DiabetesJustin M Gregory, Guillaume Kraft, Melanie F Scott, et al.
Circulation|June 28, 2022
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced MyocarditisHan Zhu, Francisco X Galdos, Daniel Lee, et al.
Clinical Chemistry|January 4, 2021
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response MonitoringJared C Nesvet, Katie A Antilla, Danielle S Pancirer, et al.
Cancer Discovery|October 1, 2013
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumorsNadine S Jahchan, Joel T Dudley, Pawel K Mazur, et al.
Pageof 49